 |
|
|
NVAX is reaching new 52-week highs as investors look toward fall. |
|
|
Released on Tuesday, July 31, 2012, 10:00 PM ET
Pittsburgh, PA (SpeculatingStocks) - Novavax, Inc. (NASDAQ:NVAX) is a developer of vaccines with a seasonal flu vaccine in Phase IIb clinical trials and a vaccine for avian flu in Phase I trials.
Investors look ahead and with summer half over they are looking towards fall and winter and flu season. This is the time of year that a flu-related stock could see quite a run.
NVAX could be that flu-related stock this year that sees a big run into the end of summer and into fall. NVAX has already traded up from around the $1.25 level to a 52-week high of $2.24. Volume in NVAX shares has ticked up significantly over the past month.
NVAX will be reporting Q2 revenue on August 3rd. NVAX has been seeing revenue traction with revenue of $14.6 million in 2011, up from $343k in 2010.
With over $20 million on the balance sheet as of last quarter and long-term debt of only $400k as well as a strong flu vaccine pipeline, it looks like NVAX could be quite the winner in the 2nd half of 2012.
Find more stocks on the SpeculatingStocks homepage.
Comments:
